bullish

3SBio Inc

3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug

Alopecia drug Mandi recorded revenue growth of 40%+ in 1H22. With sound financial profile, strong portfolio of market leading drugs, and rich pipeline, 3SBio is an attractive investment idea.

Equity Bottom-Up
397 Views, 01 Dec 2022 21:38
SUMMARY
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now

Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • 3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug
    01 Dec 2022
  • 3SBio Inc (1530 HK): Core Biopharmaceutical Portfolio On A Double-Digit Growth Path
    17 Jun 2022
x